Trial Profile
An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 05 Feb 2021 Results published in the Clinical Pharmacokinetics
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020.
- 22 Feb 2019 Status changed from active, no longer recruiting to completed.